Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.

Torres T, Yeung J, Prajapati VH, Ribero S, Balato A, Marzano AV, Cruz MJ, Paiva Lopes MJ, Lazaridou E, Carrascosa JM, Alvarenga JM, Farinha P, Duarte B, Munera-Campos M, Sood S, Rankin BD, Ortoncelli M, Caccavale S, Ferrucci SM, Pires Rosa G, Daponte AI, Silvi G, Peris K, Gori N, Prignano F, Kolios A, Herranz P, Gregoriou S, Rompoti N, Gkalpakiotis S, Chiricozzi A

Open source

DOI: 10.1007/s13555-025-01453-8
Published: 2025 Aug
Container: Dermatology and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s13555-025-01453-8,
  title = {Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.},
  author = {Torres T and Yeung J and Prajapati VH and Ribero S and Balato A and Marzano AV and Cruz MJ and Paiva Lopes MJ and Lazaridou E and Carrascosa JM and Alvarenga JM and Farinha P and Duarte B and Munera-Campos M and Sood S and Rankin BD and Ortoncelli M and Caccavale S and Ferrucci SM and Pires Rosa G and Daponte AI and Silvi G and Peris K and Gori N and Prignano F and Kolios A and Herranz P and Gregoriou S and Rompoti N and Gkalpakiotis S and Chiricozzi A},
  year = {2025},
  journal = {Dermatology and therapy},
  doi = {10.1007/s13555-025-01453-8},
  url = {https://doi.org/10.1007/s13555-025-01453-8}
}

RIS

TY  - JOUR
TI  - Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.
AU  - Torres T
AU  - Yeung J
AU  - Prajapati VH
AU  - Ribero S
AU  - Balato A
AU  - Marzano AV
AU  - Cruz MJ
AU  - Paiva Lopes MJ
AU  - Lazaridou E
AU  - Carrascosa JM
AU  - Alvarenga JM
AU  - Farinha P
AU  - Duarte B
AU  - Munera-Campos M
AU  - Sood S
AU  - Rankin BD
AU  - Ortoncelli M
AU  - Caccavale S
AU  - Ferrucci SM
AU  - Pires Rosa G
AU  - Daponte AI
AU  - Silvi G
AU  - Peris K
AU  - Gori N
AU  - Prignano F
AU  - Kolios A
AU  - Herranz P
AU  - Gregoriou S
AU  - Rompoti N
AU  - Gkalpakiotis S
AU  - Chiricozzi A
PY  - 2025
JO  - Dermatology and therapy
DO  - 10.1007/s13555-025-01453-8
UR  - https://doi.org/10.1007/s13555-025-01453-8
ER  -

APA

T, T., J, Y., VH, P., S, R., A, B., AV, M., MJ, C., MJ, P. L., E, L., JM, C., JM, A., P, F., B, D., M, M., S, S., BD, R., M, O., S, C., SM, F., G, P. R., AI, D., G, S., K, P., N, G., F, P., A, K., P, H., S, G., N, R., S, G., & A, C. (2025). Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.. Dermatology and therapy. https://doi.org/10.1007/s13555-025-01453-8

Source records

pubmed · retrieved 2026-09-26T14:10:43.708Z